Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Diego Teyssonneau
Observed names:
D. Teyssonneau,
Diego Teysonneau,
Teysonneau, Diego
Institution:
Institut Bergonié
Observed institutions:
Université de Bordeaux,
Centre Hospitalier Universitaire de Bordeaux,
Hôpital Saint-André,
Institut Bergonié
ORCID:
0000-0002-9687-3759
Observed ORCID:
0000-0002-9687-3759
OpenAlex ID:
A5008107420
Prostate cancer and PARP inhibitors: progress and challenges
2021
·
Diego Teyssonneau
, Henri Margot
, et al.
·
Journal of Hematology & Oncology
·
160
PDF
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
2025
·
Florent Peyraud
, Jean-Philippe Guegan
, et al.
·
Med
·
77
PDF
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response
2024
·
Jean-Philippe Guégan
, Florent Peyraud
, et al.
·
Cell Reports Medicine
·
53
Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment
2017
·
D. Teyssonneau
, S. Cousin
, et al.
·
Annals of Oncology
·
23
Treatment of spinal metastases in renal cell carcinoma: A critical review
2018
·
Diego Teyssonneau
, Marine Gross-Goupil
, et al.
·
Critical Reviews in Oncology/Hematology
·
22
Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response
2017
·
Diego Teyssonneau
, Amaury Daste
, et al.
·
BMC Cancer
·
18
PDF
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
2023
·
Arnaud Bayle
, Laila Belcaid
, et al.
·
Molecular Cancer
·
17
PDF
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
2022
·
Diego Teyssonneau
, Antoine Thiery-Vuillemin
, et al.
·
Journal of Clinical Medicine
·
15
PDF
Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide study
2024
·
Elena Paillaud
, Angéline Galvin
, et al.
·
Patient Education and Counseling
·
13
Gastrointestinal Metastases in Renal Cell Carcinoma: A Retrospective Multicenter GETUG (Groupe D’Étude Des Tumeurs Uro-Génitales) Study
2023
·
F. Carneiro
, A. Vinceneux
, et al.
·
European Journal of Cancer
·
12
PDF
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials
2024
·
Camille Baudelin
, Paul Sargos
, et al.
·
Critical Reviews in Oncology/Hematology
·
11
Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
2021
·
Cedric Pobel
, Edouard Auclin
, et al.
·
Cancer Medicine
·
9
PDF
PARP inhibitors in prostate cancers, is it time for combinations?
2024
·
Diego Teyssonneau
, Charles Dariane
, et al.
·
Therapeutic Advances in Medical Oncology
·
6
PDF
Olaratumab for soft tissue sarcoma
2017
·
Diego Teyssonneau
, Antoine Italiano
·
Expert Opinion on Biological Therapy
·
5
Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancer
2025
·
Romain Iaxx
, Diego Teyssonneau
, et al.
·
Current Opinion in Urology
·
3
Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol
2024
·
Paul Sargos
, Carine Bellera
, et al.
·
European Urology Oncology
·
2
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study
2025
·
Thibaut Reverdy
, Floriane Izarn
, et al.
·
Clinical Genitourinary Cancer
·
1
PDF
A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).
2024
·
Guilhem Roubaud
, Carine A. Bellera
, et al.
·
Journal of Clinical Oncology
·
1
Health literacy in patients with cancer: A multicenter national study.
2022
·
Elena Paillaud
, Angéline Galvin
, et al.
·
Journal of Clinical Oncology
·
1
711P Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
2021
·
C.J. Pobel
, D. Teyssonneau
, et al.
·
Annals of Oncology
·
1
PDF
1175 Combining PSMAxCD28 costimulatory T cell engager (TCE) JNJ-87189401 with pasritamig (KLK2xCD3): first-in-human phase 1 results of a dual-antigen targeted TCE regimen in prostate cancer
2026
·
Laura S Graham
, Christophe Massard
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Machine Learning Models Combining [68Ga]Ga-PSMA-11 PET Radiomics and Clinical Features to Predict Overall Survival for Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA Radioligand Therapy
2026
·
Lucas Edouard
, Léa Papillon
, et al.
·
European Urology Oncology
Impact of FGFR3 alterations on first-line platinum based chemotherapy in patients with metastatic or locally advanced urothelial carcinoma: The retrospective IFUCA study.
2026
·
Thibaut Reverdy
, Floriane Izarne
, et al.
·
Journal of Clinical Oncology
PDF
Machine learning models combining 68 Ga-PSMA PET radiomics and clinical features to predict overall survival for mCRPC patients treated with 177 Lu-PSMA radioligand therapy.
2026
·
Lucas Edouard
, Loïc Ferrer
, et al.
·
Journal of Clinical Oncology
PDF
3124eP Impact of FGFR3 alteration on first-line platinum based chemotherapy in patients with metastatic or locally advanced Urothelial CArcinoma : The retrospective IFUCA study
2025
·
T. Reverdy
, F.J. Izarn
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
34
Citation count:
450
H-index:
11
I10-index:
11
Year
Topic
Type